Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Cell Motility|January 1, 1983
Correlation between distribution of cytoskeletal proteins and release of alkaline phosphatase-rich vesicles by epiphyseal chondrocytes in primary cultureJ E Hale, J E Chin, Y Ishikawa, et al.
The Journal of Infectious Diseases|February 18, 1998
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasiaJ R Groothuis, S J King, D A Hogerman, et al.
Vaccine|January 1, 1993
Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunizationS W Hildreth, R R Baggs, D G Brownstein, et al.
Vaccine|March 1, 1991
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV)B R Murphy, G A Prince, P L Collins, et al.
Studies in Health Technology and Informatics|February 19, 2005
A feasibility study of yarns and fibers with annexed electronic functions: the ARIANNE projectA Bonfiglio, D De Rossi, T Kirstein, et al.
Life Sciences in Space Research|April 23, 2021
Biology and crop production in Space environments: Challenges and opportunitiesS De Pascale, C Arena, G Aronne, et al.
Acta Neurochirurgica. Supplement|November 26, 2010
Treatment of symptomatic lumbar spinal degenerative pathologies by means of combined conservative biochemical treatmentsA Alexandre, L Corò, R Paradiso, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|January 24, 2014
[Comparison of cultural methods for the recovery of Pseudomonas aeruginosa: the UNI EN ISO 16266 reference method and the alternative method Pseudalert®]M Semproni, R Briancesco, S Giampaoli, et al.
DNA (Mary Ann Liebert, Inc.)|November 1, 1989
Alkaline phosphatase fusions to the respiratory syncytial virus F protein as an approach to analyze its membrane topologyA Martin-Gallardo, R A Deich, K A Fien, et al.
Expert Review of Vaccines|September 16, 2024
Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacyMark A Fletcher, Beate Schmoele-Thoma, Jelena Vojicic, et al.
Pageof 8